# US 2003/0232019 A1 · Inhalable formulations for sustained release

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0232019 A1
- Document ID: US20030232019A1
- Status: Published application
- Kind: A1
- Application number: 10/371,398
- Filed: 2003-02-20
- Published: 2003-12-18
- Earliest claimed: 2002-02-22
- Assignees: Advanced Inhalation Research, Inc.
- Inventors: Sujit K. Basu; Katharina Elbert; Jeffrey Hrkach; Giovanni Caponetti
- Web page: https://patentgrep.com/patent/US20030232019A1

## CPC

- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is based, in part, on the unexpected discovery that aerosol particle formulations for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising an asymmetric phospholipid exhibit sustained release and/or sustained action of the agent. In some embodiments, as an alternative to one or more asymmetric phospholipids or in addition to one or more asymmetric phospholipids, the instant particles comprise one or more glycerol fatty acid esters. The present invention is directed to spray dried non-polymeric particles for pulmonary delivery and sustained release of a therapeutic, prophylactic or diagnostic agent and methods for delivery of said particles to the pulmonary system, the particles comprising a therapeutic, prophylactic or diagnostic agent and an asymmetric phospholipid and/or one or more glycerol fatty acid esters. In one embodiment, the particles comprise a combination of phospholipids wherein at least one of the phospholipids is an asymmetric phospholipid. In another embodiment, the particles comprise one or more phospholipids and one or more glycerol fatty acid esters.

## Claims

### Claim 1

Spray dried non-polymeric particles for pulmonary delivery and sustained release of a therapeutic, prophylactic or diagnostic agent comprising:
(a) a therapeutic, prophylactic or diagnostic agent; and
(b) an asymmetric phospholipid;
said particles having a tap density of less than about 0.4 g/cm3.

### Claim 2 (depends on 1)

The particles of claim 1 wherein the particles have a tap density less than or equal to about 0.3 g/cm3.

### Claim 3 (depends on 2)

The particles of claim 2 wherein the particles have a tap density less than or equal to about 0.2 g/cm3.

### Claim 4 (depends on 3)

The particles of claim 3 wherein the particles have a tap density less than or equal to about 0.1 g/cm3.

### Claim 5 (depends on 4)

The particles of claim 4 wherein the particles have a tap density less than or equal to about 0.05 g/cm3.

### Claim 6 (depends on 1)

The particles of claim 1 wherein the particles have a mean geometric diameter of between about 5 microns and about 30 microns.

### Claim 7 (depends on 6)

The particles of claim 6 wherein the particles have a mean geometric diameter of between about 8 microns and 20 microns.

### Claim 8 (depends on 1)

The particles of claim 1 wherein the particles have an aerodynamic diameter of between about 1 micron and about 5 microns.

### Claim 9 (depends on 8)

The particles of claim 8 wherein the particles have an aerodynamic diameter of between about 1 micron and 3 microns.

### Claim 10 (depends on 8)

The particles of claim 8 wherein the particles have an aerodynamic diameter of between about 3 microns and 5 microns.

### Claim 11 (depends on 1)

The particles of claim 1 further comprising a compound selected from the group consisting of polysaccharides, sugars, buffer salts, proteins, lipids, surfactants, cholesterol, fatty acids, fatty acid esters and any combination thereof.

### Claim 12 (depends on 1)

The particles of claim 1 wherein the particles comprise at least about 2 weight percent of the therapeutic, prophylactic or diagnostic agent.

### Claim 13 (depends on 1)

The particles of claim 1 wherein the particles comprise at least about 6 weight percent of the therapeutic, prophylactic or diagnostic agent.

### Claim 14 (depends on 1)

The particles of claim 1 wherein the particles comprise about 5 to 10 weight percent of the therapeutic, prophylactic or diagnostic agent.

### Claim 15 (depends on 14)

The particles of claim 14 wherein the particles comprise about 8 weight percent of the therapeutic, prophylactic or diagnostic agent.

### Claim 16 (depends on 1)

The particles of claim 1 wherein the therapeutic, prophylactic or diagnostic agent is albuterol, or a salt thereof.

### Claim 17 (depends on 1)

The particles of claim 1 wherein the therapeutic, prophylactic or diagnostic agent is salmeterol, or a salt thereof.

### Claim 18 (depends on 1)

The particles of claim 1 wherein the therapeutic, prophylactic or diagnostic agent is selected from the group consisting of estrone, estradiol, estriol, and salts thereof.

### Claim 19 (depends on 1)

The particles of claim 1 wherein the therapeutic, prophylactic or diagnostic agent is a protein or peptide.

### Claim 20 (depends on 1)

The particles of claim 1 wherein the therapeutic, prophylactic or diagnostic agent is hydrophilic.

### Claim 21 (depends on 1)

The particles of claim 1 wherein the therapeutic, prophylactic or diagnostic agent is hydrophobic.

### Claim 22 (depends on 1)

The particles of claim 1 wherein the asymmetric phospholipid is selected from the group consisting of 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC) and 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC).

### Claim 23 (depends on 1)

The particles of claim 1 further comprising an identical, or symmetric, chain phospholipid.

### Claim 24 (depends on 23)

The particles of claim 23 wherein the identical chain phospholipid is selected from the group consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

### Claim 25 (depends on 1)

The particles of claim 1 wherein the particles comprise a combination of asymmetric phospholipids.

### Claim 26 (depends on 1)

The particles of claim 1 wherein the particles comprise about 70 to 80 weight percent phospholipid or combination of phospholipids.

### Claim 27 (depends on 26)

The particles of claim 26 wherein the particles comprise about 76 weight percent phospholipid or combination of phospholipids.

### Claim 28 (depends on 1)

The particles of claim 1 further comprising an amino acid.

### Claim 29 (depends on 28)

The particles of claim 28 wherein the amino acid is hydrophobic.

### Claim 30 (depends on 28)

The particles of claim 28 wherein the amino acid is leucine.

### Claim 31 (depends on 30)

The particles of claim 30 wherein leucine is present in a concentration of about 10 to 20 weight percent.

### Claim 32 (depends on 1)

A method comprising delivering via the pulmonary system of a patient in need of treatment, prophylaxis or diagnosis an effective amount of the particles of claim 1.

### Claim 33

A method for delivering a sustained release of a therapeutic, prophylactic or diagnostic via the pulmonary system, the method comprising:
administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of spray dried non-polymeric particles comprising:
(a) a therapeutic, prophylactic or diagnostic agent; and
(b) an asymmetric phospholipid;
said particles having a tap density of less than about 0.4 g/cm3.

### Claim 34 (depends on 33)

The method of claim 33 wherein the particles have a tap density less than or equal to about 0.3 g/cm3.

### Claim 35 (depends on 34)

The method of claim 34 wherein the particles have a tap density less than or equal to about 0.2 g/cm3.

### Claim 36 (depends on 35)

The method of claim 35 wherein the particles have a tap density less than or equal to about 0.1 g/cm3.

### Claim 37 (depends on 36)

The method of claim 36 wherein the particles have a tap density less than or equal to about 0.05 g/cm3.

### Claim 38 (depends on 33)

The method of claim 33 wherein the particles have a mean geometric diameter of between about 5 microns and about 30 microns.

### Claim 39 (depends on 38)

The method of claim 38 wherein the particles have a mean geometric diameter of between about 8 microns and 20 microns.

### Claim 40 (depends on 33)

The method of claim 33 wherein the particles have an aerodynamic diameter of between about 1 micron and 5 microns.

### Claim 41 (depends on 40)

The method of claim 40 wherein the particles have an aerodynamic diameter of between about 1 micron and 3 microns.

### Claim 42 (depends on 40)

The method of claim 40 wherein the particles have an aerodynamic diameter of between about 3 microns and 5 microns.

### Claim 43 (depends on 33)

The method of claim 33 wherein the particles further comprise a compound selected from the group consisting of polysaccharides, sugars, buffer salts, proteins, lipids, surfactants, cholesterol, fatty acids, fatty acid esters and any combination thereof.

### Claim 44 (depends on 33)

The method of claim 33 wherein the particles comprise at least about 2 weight percent of the therapeutic, prophylactic or diagnostic agent.

### Claim 45 (depends on 44)

The method of claim 44 wherein the particles comprise at least about 6 weight percent of the therapeutic, prophylactic or diagnostic agent.

### Claim 46 (depends on 33)

The method of claim 33 wherein the particles comprise about 5 to 10 weight percent of the therapeutic, prophylactic or diagnostic agent.

### Claim 47 (depends on 46)

The method of claim 46 wherein the particles comprise about 8 weight percent of the therapeutic, prophylactic or diagnostic agent.

### Claim 48 (depends on 33)

The method of claim 33 wherein the therapeutic, prophylactic or diagnostic agent is albuterol, or a salt thereof.

### Claim 49 (depends on 33)

The method of claim 33 wherein the therapeutic, prophylactic or diagnostic agent is salmeterol, or a salt thereof.

### Claim 50 (depends on 33)

The method of claim 33 wherein the therapeutic, prophylactic or diagnostic agent is selected from the group consisting of estrone, estradiol, estriol, and salts thereof.

### Claim 51 (depends on 33)

The method of claim 33 wherein the therapeutic, prophylactic or diagnostic agent is a protein or peptide.

### Claim 52 (depends on 33)

The method of claim 33 wherein the therapeutic, prophylactic or diagnostic agent is hydrophilic.

### Claim 53 (depends on 33)

The method of claim 33 wherein the therapeutic, prophylactic or diagnostic agent is hydrophobic.

### Claim 54 (depends on 33)

The method of claim 33 wherein the asymmetric phospholipid is selected from the group consisting of 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC) and 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC).

### Claim 55 (depends on 33)

The method of claim 33 wherein the particles further comprise an identical, or symmetric, chain phospholipid.

### Claim 56 (depends on 55)

The method of claim 55 wherein the identical chain phospholipid is selected from the group consisting of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

### Claim 57 (depends on 33)

The method of claim 33 wherein the particles comprise a combination of asymmetric phospholipids.

### Claim 58 (depends on 33)

The method of claim 33 wherein the particles comprise about 70 to 80 weight percent phospholipid or combination of phospholipids.

### Claim 59 (depends on 58)

The method of claim 58 wherein the particles comprise about 76 weight percent phospholipid or combination of phospholipids.

### Claim 60 (depends on 33)

The method of claim 33 wherein the particles further comprise an amino acid.

### Claim 61 (depends on 60)

The method of claim 60 wherein the amino acid is hydrophobic.

### Claim 62 (depends on 60)

The method of claim 60 wherein the amino acid is leucine.

### Claim 63 (depends on 62)

The method of claim 62 wherein leucine is present in a concentration of about 10 to 20 weight percent.

### Claim 64 (depends on 33)

The method of claim 33 wherein delivery is primarily to the deep lung.

### Claim 65 (depends on 33)

The method of claim 33 wherein delivery is primarily to the central airways.

### Claim 66 (depends on 33)

The method of claim 33 wherein delivery is primarily to the small airways.

### Claim 67 (depends on 33)

The method of claim 33 wherein delivery is primarily to the upper airways.

### Claim 68 (depends on 33)

The method of claim 33 wherein administration is via a dry powder inhaler.

### Claim 69

Spray dried non-polymeric particles for pulmonary delivery and sustained release of a therapeutic, prophylactic or diagnostic agent comprising
(a) about 5 to 15 weight percent albuterol sulfate;
(b) about 70 to 80 weight percent of an asymmetric phospholipid or combination of phospholipids wherein at least one phospholipid is asymmetric; and
(c) about 10 to 20 weight percent leucine;
said particles having a tap density of less than about 0.4 g/cm3.

### Claim 70 (depends on 69)

The particles of claim 69 wherein the asymmetric phospholipid is selected from the group consisting of 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC) and 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC).

### Claim 71

A method for delivering a sustained release of a therapeutic, prophylactic or diagnostic via the pulmonary system, the method comprising:
administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of spray dried non-polymeric particles comprising
(a) about 5 to 15 weight percent albuterol sulfate;
(b) about 70 to 80 weight percent of an asymmetric phospholipid or combination of phospholipids wherein at least one phospholipid is asymmetric; and
(c) about 10 to 20 weight percent leucine;
said particles having a tap density of less than about 0.4 g/cm3.

### Claim 72 (depends on 71)

The method of claim 71 wherein the asymmetric phospholipid is selected from the group consisting of 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC) and 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC).

### Claim 73

Spray dried particles for pulmonary delivery and sustained release of a therapeutic, prophylactic or diagnostic agent comprising:
(a) a therapeutic, prophylactic or diagnostic agent;
(b) an amino acid, or a salt thereof; and
(c) an asymmetric phospholipid;
said particles having a tap density of less than about 0.4 g/cm3.

### Claim 74 (depends on 73)

A method for delivering a sustained release of a therapeutic, prophylactic or diagnostic via the pulmonary system, the method comprising:
administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of the spray dried particles of claim 73.

### Claim 75

Particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent, the particles comprising:
(a) a therapeutic, prophylactic or diagnostic agent;
(b) a glycerol fatty acid ester or a combination of glycerol fatty acid esters; and
(c) a phospholipid or combination of phospholipids;
said particles having a tap density of less than about 0.4. g/cm3.

### Claim 76 (depends on 75)

The particles of claim 75 wherein the glycerol fatty acid ester or combination of glycerol fatty acid esters is represented by the structural formula
8
wherein R1, R2, and R3 are, independently, hydroxide, palmitate, or stearate and at least one of R1, R2, and R3 is non-hydroxide.

### Claim 77 (depends on 75)

The particles of claim 75 wherein the glycerol fatty acid ester or combination of glycerol fatty acid esters is glyceryl palmitostearate.

### Claim 78 (depends on 75)

The particles of claim 75 wherein the glycerol fatty acid ester or combination of glycerol fatty acid esters is present at a concentration of about 1 to about 25 percent by weight.

### Claim 79 (depends on 78)

The particles of claim 78 wherein the glycerol fatty acid ester or combination of glycerol fatty acid esters is present at a concentration of about 1 to about 10 percent by weight.

### Claim 80 (depends on 75)

The particles of claim 75 further comprising a polyglycolized glyceride.

### Claim 81 (depends on 75)

The particles of claim 75 further comprising an amino acid or a salt thereof.

### Claim 82 (depends on 81)

The particles of claim 81 wherein the amino acid or salt thereof is leucine.

### Claim 83 (depends on 75)

The particles of claim 75 further comprising a material selected from the group consisting of polysaccharides, sugars, polymers, cyclodextrins, lipids, buffer salts, surfactants, cholesterol, fatty acids, fatty acid esters, proteins, peptides, and any combination thereof.

### Claim 84 (depends on 75)

The particles of claim 75 wherein the particles are spray dried.

### Claim 85 (depends on 75)

The particles of claim 75 wherein the particles have a tap density less than or equal to about 0.3 g/cm3.

### Claim 86 (depends on 85)

The particles of claim 85 wherein the particles have a tap density less than or equal to about 0.2 g/cm3.

### Claim 87 (depends on 86)

The particles of claim 86 wherein the particles have a tap density less than or equal to about 0.1 g/cm3.

### Claim 88 (depends on 75)

The particles of claim 75 wherein the particles have a median geometric diameter of about 5 to about 25 microns.

### Claim 89 (depends on 75)

The particles of claim 75 wherein the particles have a median aerodynamic diameter of about 1 to about 5 microns.

### Claim 90 (depends on 89)

The particles of claim 89 wherein the particles have a median aerodynamic diameter of about 2 to about 4 microns.

### Claim 91 (depends on 75)

A method for delivering a therapeutic, prophylactic or diagnostic to a patient via the pulmonary system, the method comprising:
administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of the particles of claim 75.

### Claim 92

A method for delivering a sustained release of a therapeutic, prophylactic or diagnostic via the pulmonary system, the method comprising:
administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising:
(a) a therapeutic, prophylactic or diagnostic agent;
(b) a glycerol fatty acid ester or a combination of glycerol fatty acid esters; and
(c) a phospholipid or combination of phospholipids;
said particles having a tap density of less than about 0.4. g/cm3.

### Claim 93 (depends on 92)

The method of claim 92 wherein the glycerol fatty acid ester or combination of glycerol fatty acid esters is represented by the structural formula
9
wherein R1, R2, and R3 are, independently, hydroxide, palmitate, or stearate and at least one of R1, R2, and R3 is non-hydroxide.

### Claim 94 (depends on 92)

The method of claim 92 wherein the glycerol fatty acid ester or combination of glycerol fatty acid esters is glyceryl palmitostearate.

### Claim 95 (depends on 92)

The method of claim 92 wherein the glycerol fatty acid ester or combination of glycerol fatty acid esters is present at a concentration of about 1 to about 25 percent by weight.

### Claim 96 (depends on 95)

The method of claim 95 wherein the glycerol fatty acid ester or combination of glycerol fatty acid esters is present at a concentration of about 1 to about 10 percent by weight.

### Claim 97 (depends on 92)

The particles of claim 92 further comprising a polyglycolized glyceride.

### Claim 98 (depends on 92)

The method of claim 92 wherein the particles further comprise an amino acid or a salt thereof.

### Claim 99 (depends on 98)

The method of claim 98 wherein the amino acid or salt thereof is leucine.

### Claim 100 (depends on 92)

The method of claim 92 wherein the particles further comprise a material selected from the group consisting of polysaccharides, sugars, polymers, cyclodextrins, lipids, buffer salts, surfactants, cholesterol, fatty acids, fatty acid esters, proteins, peptides, and any combination thereof.

### Claim 101 (depends on 92)

The method of claim 92 wherein the particles are spray dried.

### Claim 102 (depends on 92)

The method of claim 92 wherein the particles have a tap density less than or equal to about 0.3 g/cm3.

### Claim 103 (depends on 102)

The method of claim 102 wherein the particles have a tap density less than or equal to about 0.2 g/cm3.

### Claim 104 (depends on 103)

The method of claim 103 wherein the particles have a tap density less than or equal to about 0.1 g/cm3.

### Claim 105 (depends on 92)

The method of claim 92 wherein the particles have a median geometric diameter of about 5 to about 25 microns.

### Claim 106 (depends on 92)

The method of claim 92 wherein the particles have a median aerodynamic diameter of about 1 to about 5 microns.

### Claim 107 (depends on 106)

The method of claim 106 wherein the particles have a median aerodynamic diameter of about 2 to about 4 microns.

### Claim 108 (depends on 92)

The method of claim 92 wherein the therapeutic, prophylactic or diagnostic agent has a half time of release from the particles of at least about 15 minutes.

### Claim 109 (depends on 92)

The method of claim 92 wherein the therapeutic, prophylactic or diagnostic agent has a half time of release from the particles of at least about 30 minutes.

### Claim 110 (depends on 92)

The method of claim 92 wherein particles are delivered primarily to the deep lung.

### Claim 111 (depends on 92)

The method of claim 92 wherein particles are delivered primarily to the central airways.

### Claim 112 (depends on 92)

The method of claim 92 wherein particles are delivered primarily to the upper airways.

### Claim 113 (depends on 92)

The method of claim 92 wherein the particles are administered via a dry powder inhaler.

### Claim 114

Particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent, the particles comprising:
(a) albuterol, or a salt thereof;
(b) glyceryl palmitostearate;
(c) leucine, or a salt thereof;
(d) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); and
(e) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

### Claim 115 (depends on 114)

The particles of claim 114 wherein said particles have a tap density of less than about 0.4 g/cm3.

### Claim 116 (depends on 115)

The particles of claim 115 wherein said particles have a tap density of less than about 0.2 g/cm3.

### Claim 117 (depends on 114)

The particles of claim 114 wherein the glyceryl palmitostearate is present at a concentration of about 1 to about 10 percent by weight.

### Claim 118 (depends on 114)

The particles of claim 114 wherein the albuterol is albuterol sulfate and is present in a concentration of about 5 to about 10 weight percent; the glyceryl palmitostearate is present in a concentration of about 2 to about 8 weight percent; the leucine is present in a concentration of about 13 to about 19 weight percent; and the 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) are present in a total concentration of about 65 to about 77 weight percent.

### Claim 119

A method for delivering a sustained release of a therapeutic, prophylactic or diagnostic via the pulmonary system, the method comprising:
administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising:
(a) albuterol, or a salt thereof;
(b) glyceryl palmitostearate;
(c) leucine, or a salt thereof;
(d) 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); and
(e) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

### Claim 120 (depends on 119)

The method of claim 119 wherein said particles have a tap density of less than about 0.4 g/cm3.

### Claim 121 (depends on 120)

The method of claim 120 wherein said particles have a tap density of less than about 0.2 g/cm3.

### Claim 122 (depends on 119)

The method of claim 119 wherein the glyceryl palmitostearate is present at a concentration of about 1 to about 10 percent by weight.

### Claim 123 (depends on 119)

The method of claim 119 wherein the albuterol is albuterol sulfate and is present in a concentration of about 5 to about 10 weight percent; the glyceryl palmitostearate is present in a concentration of about 2 to about 8 weight percent; the leucine is present in a concentration of about 13 to about 19 weight percent; and the 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) are present in a total concentration of about 65 to about 77 weight percent.
